The price a stock trades at can drastically impact your overall returns. If you wait for a top growth stock to come down to a ...

The Janus Henderson Global Life Sciences Fund returned -11.16% and the MSCI World Health Care IndexSM returned -11.40%. Click ...

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...

We ran that screen on Feb. 15 last year, using data as of the market close the previous day. Nvidia's (NVDA) stock has returned 80% from Feb. 14, 2024, through Tuesday, while the S&P 500 SPX has ...

Most economists expect muted U.S. economic growth in the coming quarters, and some indicators suggest a mild U.S. recession is still a possibility. It may become difficult for investors to ...

We recently published a list of Jim Cramer Discusses These 11 Stocks & President Trump’s Sovereign Wealth Fund.

Terns Pharmaceuticals' TERN-701 and TERN-601 face challenges in CML and obesity. Find out why TERN stock is not a strong buy amid tough competition.

Eli Lilly & Co. said Thursday that its Type 2 diabetes drug Mounjaro and its weight-loss and diabetes drug Zepbound drove a ...

The Dow Jones Industrial Average ( ^DJI) and the S&P 500 ( ^GSPC) both rose more than 0.2%. The tech-heavy Nasdaq Composite ( ...

Revenue in Q4 2024 increased 45% to $13.53 billion driven by volume growth from Mounjaro and Zepbound. Non-incretin revenue(i) grew by 20% compared to Q4 2023. Pipeline ...

Failed to fetch dynamically imported module: https://au.finance.yahoo.com/assets/_app/immutable/nodes/19.CVin4ONc.js ...

On an adjusted basis, the U.S. drugmaker expects to earn between $22.50 and $24.00 per share in 2025. Analysts were expecting ...